-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 7, the Guangdong Provincial Drug Trading Center issued the "Notice on Viewing the Information Related to the Guangdong Alliance's Common Diseases and Chronic Diseases Drugs for Centralized Procurement and Registration of Products in Volume".
The over-evaluation category/A purchase order/B purchase order has been planned in detail
.
The original text is as follows: All relevant units: In accordance with the relevant requirements and work arrangements of the "Guangdong Alliance Common and Chronic Disease Drugs Concentrated Procurement Document (GDYJYPDL202202)" (hereinafter referred to as the "Procurement Document"), the Guangdong Alliance is now carrying out the Guangdong Alliance Common and chronic disease drugs.
The relevant matters are notified as follows: 1.
Contents to be viewed (1) Relevant information form of registered products that meet the application conditions (see Attachment 1); (2) Over-rated/non-over-rated/A purchase order/B Purchase Order Schedule (see Annex 2)
.
2.
Time schedule From now until 17:30 on March 8, 2022
.
3.
Other requirements (1) If you have any objection to viewing the information, please use the CA certificate to log in to the drug trading system within the specified time, and fill in the feedback content through "Information Review/Feedback Management-Other Information Review/Feedback (Drugs)" , and upload the drug information review feedback form (see Annex 3 for the template) and related certification materials as required, and the feedback materials must be stamped with the official seal of the company page by page; if the feedback materials are not submitted within the specified time, it will be regarded as no objection, and the corresponding consequences will be The enterprise shall bear it by itself
.
(2) If there is a situation listed in the "Procurement Documents" that "in the enterprises applying for the same product and the same competitive unit, the person in charge of the enterprise is the same person or there is a direct controlling or management relationship", the relevant enterprises are requested to make the declaration truthfully within the specified time, and the content of the declaration The name of the specific competitive unit involved, the specific relationship with the competitive unit enterprise (the person in charge of the enterprise is the same person/existing direct controlling relationship/existing management relationship) and relevant certification materials, please refer to the above point (1) for specific requirements and application methods
.
If the declaration is not made within the specified time, it is deemed that the enterprise promises that the above-mentioned situations do not exist.
.
(3) The content of the objection feedback materials submitted by the enterprise should be true, valid, clear and complete, targeted and unambiguous, and legal and valid evidence materials (including but not limited to certification documents stamped with the official seal of the provincial drug procurement department, winning bids) should be provided in accordance with laws and regulations.
Announcement on the website, notice of winning the bid or complete screenshot of the official website, etc.
); objection feedback that is not submitted within the specified time, without corresponding supporting materials, or submitted in the specified way, will not be accepted in principle
.
(4) The enterprise shall be responsible for the authenticity, validity and legitimacy of the submitted feedback materials, and all consequences arising from errors and omissions in the submitted materials shall be borne by the enterprise itself
.
(5) Enterprises must truthfully declare relevant price information and shareholding (management) relationship.
For enterprises that make false reports, omissions, concealment or submit false materials, once verified, they will be dealt with in accordance with the relevant provisions of the "Procurement Documents", and the corresponding responsibilities will be The enterprise shall bear it by itself
.
IV.
Contact information (1) Online customer service on the official website of Guangdong Drug Trading Center
.
(2) Consultation telephone: 020-38036183, 020-38036197 (working days: 8:30-12:00 14:00-17:30)
.
Guangdong Drug Trading Center March 7, 2022
The over-evaluation category/A purchase order/B purchase order has been planned in detail
.
The original text is as follows: All relevant units: In accordance with the relevant requirements and work arrangements of the "Guangdong Alliance Common and Chronic Disease Drugs Concentrated Procurement Document (GDYJYPDL202202)" (hereinafter referred to as the "Procurement Document"), the Guangdong Alliance is now carrying out the Guangdong Alliance Common and chronic disease drugs.
The relevant matters are notified as follows: 1.
Contents to be viewed (1) Relevant information form of registered products that meet the application conditions (see Attachment 1); (2) Over-rated/non-over-rated/A purchase order/B Purchase Order Schedule (see Annex 2)
.
2.
Time schedule From now until 17:30 on March 8, 2022
.
3.
Other requirements (1) If you have any objection to viewing the information, please use the CA certificate to log in to the drug trading system within the specified time, and fill in the feedback content through "Information Review/Feedback Management-Other Information Review/Feedback (Drugs)" , and upload the drug information review feedback form (see Annex 3 for the template) and related certification materials as required, and the feedback materials must be stamped with the official seal of the company page by page; if the feedback materials are not submitted within the specified time, it will be regarded as no objection, and the corresponding consequences will be The enterprise shall bear it by itself
.
(2) If there is a situation listed in the "Procurement Documents" that "in the enterprises applying for the same product and the same competitive unit, the person in charge of the enterprise is the same person or there is a direct controlling or management relationship", the relevant enterprises are requested to make the declaration truthfully within the specified time, and the content of the declaration The name of the specific competitive unit involved, the specific relationship with the competitive unit enterprise (the person in charge of the enterprise is the same person/existing direct controlling relationship/existing management relationship) and relevant certification materials, please refer to the above point (1) for specific requirements and application methods
.
If the declaration is not made within the specified time, it is deemed that the enterprise promises that the above-mentioned situations do not exist.
.
(3) The content of the objection feedback materials submitted by the enterprise should be true, valid, clear and complete, targeted and unambiguous, and legal and valid evidence materials (including but not limited to certification documents stamped with the official seal of the provincial drug procurement department, winning bids) should be provided in accordance with laws and regulations.
Announcement on the website, notice of winning the bid or complete screenshot of the official website, etc.
); objection feedback that is not submitted within the specified time, without corresponding supporting materials, or submitted in the specified way, will not be accepted in principle
.
(4) The enterprise shall be responsible for the authenticity, validity and legitimacy of the submitted feedback materials, and all consequences arising from errors and omissions in the submitted materials shall be borne by the enterprise itself
.
(5) Enterprises must truthfully declare relevant price information and shareholding (management) relationship.
For enterprises that make false reports, omissions, concealment or submit false materials, once verified, they will be dealt with in accordance with the relevant provisions of the "Procurement Documents", and the corresponding responsibilities will be The enterprise shall bear it by itself
.
IV.
Contact information (1) Online customer service on the official website of Guangdong Drug Trading Center
.
(2) Consultation telephone: 020-38036183, 020-38036197 (working days: 8:30-12:00 14:00-17:30)
.
Guangdong Drug Trading Center March 7, 2022
